SEC Form 4 · accession 0001144204-15-046274
Altimmune, Inc. · ALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey W. Runge
Director
Period of report
Aug 2, 2015
Accepted (ET)
Aug 4, 2015 · 7:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001326190
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $1.69 | Aug 2, 2015 | A | 20,000 | A | Aug 2, 2016 | Aug 1, 2025 | Common Stock | 20,000 | 20,000 | D |
Explanation of responses
- F1The Issuer's Board of Directors approved the stock option grant on a non-trading day. On July 31, 2015, the last trading day prior to the date of grant, the closing price of the Issuer's common stock was $1.69 per share.